Ticlopidine hydrochloride displays nonlinear pharmacokinetics and clearance decreases markedly on repeated
dosing. In older volunteers, the apparent half-life of ticlopidine after a single 250 mg dose is about 12.6 hours;
with repeat dosing at 250 mg twice daily, the terminal elimination half-life rises to four to five days and steady
state levels of ticlopidine hydrochloride in plasma are obtained after approximately 14 to 21 days.